

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Relugolix for treating hormone-sensitive prostate cancer [ID6187]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| <p>During scoping, one stakeholder highlighted that African or Caribbean groups were not represented in the trial as patient subgroups. Subgroups are only presented geographically (North and South America, Europe and Asia Pacific) rather than by ethnicity. Baseline risk for African or Caribbean groups with cardiovascular risk factors and advanced prostate cancer may lead to different outcomes.</p> <p>The committee discussed the equality issue raised and agreed that its recommendations do not have a different impact on people protected by the equality legislation. The committee considered that there were no equalities issues that could be addressed by its recommendations.</p> |
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| None raised. |

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

None identified.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Equality issue considered by the committee are included in section 3.18 of final draft guidance document.

Approved by Associate Director (name): Emily Crowe **Date:** 28/06/2024